Using Key Performance Indicators (KPIs) from Medication Reconciliation (MR) to Quantify and Prevent...

18
Using Key Performance Indicators (KPIs) from Medication Reconciliation (MR) to Quantify and Prevent Future Adverse Drug Events (ADEs) Stephen Lim, TT Chih, E Fong Pharmacy, Armadale Health Service Delivering a Healthy WA

Transcript of Using Key Performance Indicators (KPIs) from Medication Reconciliation (MR) to Quantify and Prevent...

Using Key Performance Indicators (KPIs) from Medication Reconciliation (MR) to Quantify and Prevent Future

Adverse Drug Events (ADEs)

Stephen Lim, TT Chih, E FongPharmacy,

Armadale Health Service

Delivering a Healthy WA

Armadale Health Service(AHS)

Overview:

• Med Rec (MR) in AHS• Aim and Method to quantify MR• Definition of:

– Adverse Drug Events (ADEs) – Key Performance Indicators (KPIs)

• Achievements of KPIs• Prevention of future ADEs• Lesson learnt

Med Rec (MR) in AHS

• Since 2007• SQuIRe funded project• Marketed as Med Matching (M+M) program• 70-90% M+M for all admitted patients• Sustainable program • Common errors in MR

Common Drug Errors in MR

15.3

1.9

52.5

30.3

0

10

20

30

40

50

60

Wrong drug Med Duplication Med Omission Wrong dose

Exclude ADR documentation

Aims and Method to Quantify MR:

• Aims:– To quantify success or failure in MR– Use KPIs to or prevent ADEs

• Method:– Daily data collection from MR activities– Analyse data monthly using 4 KPIs

Definition of ADEs: (Adverse Drug Events Ξ Actual Drug Errors)

• Potential Drug Errors:– MR < End of Next Calendar Day (ENCD) – near misses (rectified before drug admin)– Not counted as ADEs

• Actual Drug Errors:– MR > ENCD– Counted as ADEs due to:

• Med not admin (Rx omission)• Wrong drug/dose admin (incorrect Rx)

Case study (patient AO, 70y, ♀)ADE Ξ Adverse Drug Events Ξ Actual Drug Errors

NIMC NIMC dose BPMH (Best Possible Med History)

Dose admin?

Aspirin (commission error) 100mg mane Ceased months ago 1 dose (ADE √)

Mirtazapine (commission error)

15mg nocte -ditto- 1 dose (ADE √)

Tamoxifen (commission error)

20mg nocte -ditto- 1 dose (ADE √)

Calcium (omitted Vit D) 1 d Ca plus Vit D 1 dose omitted (ADE √)

Frusemide 40mg m 20mg mane Intentional dose change (ADE X)

Olmesartan (omitted HCT) 40mg mane Olmesartan + HCT 40/12.5mg mane

1 dose omitted (ADE √)

Prochlorperazine 5mg mane

(wrong dose)

5mg tds 2 doses missed (ADE √)

Fosamax plus (commission error)

1 weekly Ceased months ago Not admin (ADE X)

Definition of 4 KPIs:

• KPI1 = ADEs per 1000 doses administered

Number ADEs ÷ Number med doses admin (30 random patients/month) X 1000

• KPI2 = ADEs per 100 med written (Rx)

Number ADEs ÷ total med written X 100

• KPI3 = Pharmacy Interventions per 100 patients

Total pharmacist clinical interventions ÷ total MR patients X100

• KPI4 = ADEs per 100 patients seen >ENCD

Number ADEs ÷ total MR patients X 100

ACHIEVEMENT : KPI1 ADEs per 1000 doses

7

5. 9

7. 1

5. 1

2. 8

4. 3

5. 4

4. 8

3. 7

3

5. 1

0

1

2

3

4

5

6

7

8

May-09 J un-09 J ul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 J an-10 Feb-10 Mar-10

Average 4.7 ADEs per 1000 doses= 1 ADE per 200 doses

Trendline ADEs

ACHIEVEMENT: KPI2 ADEs per 100 med Rx

0

5

10

15

20

25

May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10

Per

cen

tag

e

% med discrepancies

% actual ADEs

17 drug errors for every 100 meds written

4 ADEs for every 100 meds written

13 ADEs prevented due to MR

Trendline ADEs

ACHIEVEMENT: KPI3 Pharmacy Interventions per 100

patients

60

4558

140126 121

87 90

170

240

210

4026

35 38

73 69

40 45

116108 110

0

50

100

150

200

250

300

May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10

Ph

arm

ac

y in

terv

en

tio

ns

pe

r 1

00

ad

mis

sio

ns Total interventions

Med Rec interventions

122 clinical interventionsper 100 patients

64 MR activities per 100 patients

Trendline MR

KPI4: ADEs per 100 admissions(Do Nothing KPI!)

0

20

40

60

80

100

120

140

160

May-09

Jun-09

Jul-09

Aug-09

Sep-09

Oct-09

Nov-09

Dec-09

Jan-10

Feb-10

Mar-10

83 ADEs per 100 patients(MR > ENCD)

Flat trendline: Error when no MR

Prevent Future ADEs:

• Goal: ADEs to harm:

KPI1

KPI2

– ↑ KPI3

KPI4

Lesson learnt:

Lesson learnt:

KPI1 and KPI2 (≠ 0 ADE):• timely Med Rec (within ENCD)• involve all clinicians in MR

• ↑ KPI3:• 50% clinical pharmacist workload is MR related

• KPI4 remains constant if no MR • 0.8 ADE per patient

Assigning Risk Rating to ADEs

ADEs Risk Ratings

38%

57%

5% 0%

Risk rating 0 Risk rating 1 Risk rating 2 Risk Rating 3

ADEs risk rating: from 0-3

0 = near miss

1 = low (no harm has occurred)

2 = moderate (extra monitoring eg. digoxin level had to be ordered, extra obs (BP/BSL) needed, Dr reviewed patient, no extra treatment required).

3 = severe (required extra treatment, t/f to another hospital/unit, ↑ LOS, readmission)

Conclusion:

• To ADEs:• Timely Med Rec within ENCD• Involve all clinicians in MR